BiotechTube
Infant Bacterial Therapeutics

Infant Bacterial Therapeutics

Stockholm, Sweden· Est.
ibtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Infant Bacterial Therapeutics is a clinical-stage biotech focused on pioneering Live Biotherapeutic Products (LBPs) for premature infants. The company's lead asset, IBP-9414, is in late-stage development and aims to prevent necrotizing enterocolitis (NEC) and improve feeding tolerance. IBT has a broader pipeline targeting other infant diseases and antibiotic-resistant infections. As a public company based in Stockholm, it is positioned at the intersection of the microbiome and neonatal care markets.

NeonatologyGastroenterologyInfectious Diseases

Technology Platform

Discovery and pharmaceutical development of specific bacterial strains, particularly those found in breast milk, as standardized Live Biotherapeutic Products (LBPs) to modulate the infant gut microbiome.

Funding History

3
Total raised:$30M
IPOUndisclosed
Series B$20M
Series A$10M

Opportunities

IBP-9414 has the potential to be the first approved Live Biotherapeutic Product for neonates, addressing the high unmet need in NEC prevention.
The growing focus on the microbiome and antimicrobial resistance (AMR) creates a favorable environment for the company's broader pipeline.
Success could lead to acquisition interest from larger pharma companies seeking to enter the neonatal and microbiome markets.

Risk Factors

The company faces high clinical trial risk, as failure of the Phase 3 program for IBP-9414 would be catastrophic.
Regulatory uncertainty surrounds the novel LBP class, especially for infant populations.
As a pre-revenue company, it is dependent on raising capital, which may be dilutive to shareholders.

Competitive Landscape

Competition in the neonatal NEC space includes other investigational biologic approaches and probiotics used off-label. As a pioneer in neonatal LBPs, IBT faces limited direct competition but must demonstrate superiority over standard care and existing probiotic use. Larger microbiome companies (e.g., Seres, Vedanta) are focused on adult indications, creating a potential niche for IBT in pediatrics.

More companies in Sweden →